These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20926993)

  • 21. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
    Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
    New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
    PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
    Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
    Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
    Panagopoulos P; Paraskevis D; Katsarolis I; Sypsa V; Detsika M; Protopapas K; Antoniadou A; Papadopoulos A; Petrikkos G; Hatzakis A
    Int J STD AIDS; 2014 Oct; 25(12):860-5. PubMed ID: 24516079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
    Ma Q; Gelbard HA; Maggirwar SB; Dewhurst S; Gendelman HE; Peterson DR; DiFrancesco R; Hochreiter JS; Morse GD; Schifitto G
    J Neurovirol; 2013 Jun; 19(3):254-60. PubMed ID: 23737347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.
    Patterson KB; Prince HA; Stevens T; Shaheen NJ; Dellon ES; Madanick RD; Jennings S; Cohen MS; Kashuba AD
    AIDS; 2013 Jun; 27(9):1413-9. PubMed ID: 23945503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
    Calcagno A; Tettoni MC; Simiele M; Trentini L; Montrucchio C; D'Avolio A; Di Perri G; Bonora S
    J Antimicrob Chemother; 2013 Feb; 68(2):482-4. PubMed ID: 23085776
    [No Abstract]   [Full Text] [Related]  

  • 29. Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
    Kunimoto Y; Yasui H; Touda N; Okazaki M; Nakata H; Noda N; Ikeda H; Hayashi T; Takahashi S; Shinomura Y; Ishida T; Miyamoto A
    J Infect Chemother; 2013 Aug; 19(4):750-3. PubMed ID: 23053505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
    Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
    Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
    Hernández-Novoa B; Moreno A; Pérez-Elías MJ; Quereda C; Dronda F; Casado JL; Madrid-Elena N; Aguilar M; Fumero E; Moltó J; Moreno S
    J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
    Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
    HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
    Moreira FL; Marques MP; Duarte G; Lanchote VL
    J Pharm Biomed Anal; 2020 Jan; 177():112838. PubMed ID: 31525573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raltegravir pharmacokinetics during pregnancy.
    Watts DH; Stek A; Best BM; Wang J; Capparelli EV; Cressey TR; Aweeka F; Lizak P; Kreitchmann R; Burchett SK; Shapiro DE; Hawkins E; Smith E; Mirochnick M;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):375-81. PubMed ID: 25162818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients.
    Amadasi S; Odolini S; Foca E; Panzali A; Cerini C; Lonati L; Pezzoli MC; Nasta P; Casari S; Castelli F; Quiros-Roldan E
    Curr HIV Res; 2013 Dec; 11(8):642-6. PubMed ID: 24517189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
    Lozano R; Domeque N; Apesteguia AF
    J Clin Pharmacol; 2014 Feb; 54(2):161-7. PubMed ID: 24243081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.
    Tempestilli M; Gentilotti E; Tommasi C; Nicastri E; Martini F; De Nardo P; Narciso P; Pucillo LP
    Int Immunopharmacol; 2013 Aug; 16(4):492-7. PubMed ID: 23707228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen.
    Tunjungputri RN; Van Der Ven AJ; Schonsberg A; Mathan TS; Koopmans P; Roest M; Fijnheer R; Groot PG; de Mast Q
    AIDS; 2014 Sep; 28(14):2091-6. PubMed ID: 25265076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of oxidative stress on the pharmacokinetics and hepatic metabolism of atazanavir in rats.
    Kobuchi S; Fukushima K; Aoyama H; Ito Y; Sugioka N; Takada K
    Free Radic Res; 2013 Apr; 47(4):291-300. PubMed ID: 23351068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.